Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P37840

UPID:
SYUA_HUMAN

ALTERNATIVE NAMES:
Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor

ALTERNATIVE UPACC:
P37840; A8K2A4; Q13701; Q4JHI3; Q6IAU6

BACKGROUND:
The protein Alpha-synuclein, alternatively named Non-A beta component of AD amyloid, is integral to neuronal synaptic function. It enhances synaptic vesicle priming and fusion, and is vital for neurotransmitter release. Its role extends to acting as a chaperone for synaptic fusion components and regulating dopamine neurotransmission, crucial for brain function.

THERAPEUTIC SIGNIFICANCE:
Given its involvement in Parkinson's disease and Dementia with Lewy bodies, understanding the role of Alpha-synuclein could open doors to potential therapeutic strategies. Its direct association with these neurodegenerative diseases underscores the importance of targeting alpha-synuclein in drug discovery efforts.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.